Medannex Ltd

Dr Fiona Dempsey and Dr Henry Hays enjoyed the vibrant #bioProcessUK conference last week at St George's Hall, Liverpool. Engaging sessions covering policy, trends and #sustainability in life sciences as well as many great conversations with industry contacts old and new. BioIndustry Association (BIA)

Great to catch up with old friends and colleagues in London this week and to make some important new connections as well. Thanks to LSX - partnering for Life Science eXecutives for showcasing Medannex at #Investival. Ian Abercrombie Scott Crichton James Ingham

Hello all, I am looking to hire a research associate to join my team and work with Medannex Ltd to investigate the mechanism of their cancer treatment, MDX-124. This is a full-time role running from November 2024 to March 2025. Interested candidates can apply with a CV and covering letter by 31st October 2024. For more details and to apply, please visit: https://lnkd.in/epgax2kG For any queries, contact me at hussein.al-ali@aru.ac.uk.

An excellent article by Innovate UK's Head of Medicines Dr Karen Spink highlighting the importance of putting the child first when creating future life-changing cancer therapies. Medannex Ltd are proud to be part of this mission as we develop a first-in-class therapy for the rare childhood bone cancer, paediatric osteosarcoma. Deep Science Ventures https://lnkd.in/eKJEZV6c

Thanks to Burness Paull LLP and the Scottish Lifesciences Association for inviting our Director of Scientific Operations Dr Fiona Dempsey to speak at their recent women's health event in Edinburgh. Our first-in-class therapy MDX-124 has significant potential as a novel treatment for various cancers including triple-negative breast and ovarian. We're grateful for the opportunity to highlight this potential alongside excellent speakers from Ferring Controlled Therapeutics, Emblation, Talking Medicines and Microbira Limited. Thanks also to Dr Janet Halliday for chairing this important and enlightening event.

Delighted that Hussein Al Ali has been awarded grant funding to illuminate our first-in-class agent's role in mediating DNA damage and repair pathways in cancer. This work is important for the ongoing clinical study of MDX-124 as we prepare to evaluate efficacy in combination with other cancer therapies. Anglia Ruskin University

Just back from a fabulous #ESMO24 discussing the latest exciting updates from our first-in-human study with clinicians and collaborators. We're looking forward to sharing our Phase 1 oncology data next year. Ian Abercrombie Fiona Dempsey Colin Tennant

Thanks to LSX - partnering for Life Science eXecutives for offering our Operations Director James Ingham the opportunity to introduce our first-in-class #therapeutic to investors and industry colleagues at LSX USA Congress in Boston, MA. We’re excited to share the very encouraging signals emerging from our ongoing Phase 1b #oncology study ('ATTAINMENT'). #LSXUSA

We're very grateful to Innovate UK for this significant grant award as part of their Cancer Therapeutics programme.    This non-dilutive funding will allow us to prepare our first-in-class anti-annexin-A1 therapy (MDX-124) for a clinical study in the rare childhood bone cancer, paediatric osteosarcoma.    To quote Lord Vallance (Minister for Science): '...this funding is an integral part of our mission to tackle cancer through innovative treatments that could benefit patients of all ages, and give innovative small businesses the support they need to scale-up the development of their groundbreaking ideas'.   MDX-124 is currently showing interesting activity, with no toxicity concerns, in a Phase 1b clinical oncology study in adults, and we look forward to making it available to paediatric clinicians as soon as possible.   https://lnkd.in/eg5RsCu8 #CancerTherapeutics #InnovateUKFunded

We’re thrilled to announce an Innovate UK ‘Transforming Cancer Therapeutics’ grant award for a £313,000 project to tackle bone cancer in children. We’ll be working with Chris Parris' team at Anglia Ruskin University and world-leading paediatric oncologists led by Pamela Kearns to deliver this important project. Recent data mining of a paediatric genomics database and staining of tumour tissue revealed that our target, #annexin-A1, is highly expressed in #osteosarcoma, so our anti-annexin-A1 antibody (MDX-124) is a prime candidate to treat this rare disease. We’re grateful to Innovate UK for this resounding endorsement of the potential of our first-in-class therapy to make a real difference to osteosarcoma patients and their families and we’re excited to drive the project forward with the support of our scientific collaborators and specialist clinical advisors. Full story here: https://lnkd.in/ebmeK5dy Ian Abercrombie Fiona Dempsey James Ingham Henry Hays Scott Crichton Paul Flook Lisa Yule Colin Tennant